Cabozantinib: a new perspective for advanced bone sarcoma
Mené en France sur 90 patients atteints d'un sarcome d'Ewing ou d'un ostéosarcome de stade avancé (durée médiane de suivie : environ 31 mois), cet essai multicentrique simple bras de phase II évalue l'efficacité, du point de vue de la réponse objective, du cabozantinib, un inhibiteur de la kinase MET et du récepteur VEGFR2
Current multimodal therapeutic approaches have improved the prognosis of patients with Ewing sarcoma and osteosarcoma, with a 5-year overall survival rate of around 60–70%. Nevertheless, patients with recurrent or refractory disease have a poor prognosis, with a 5-year overall survival rate of less than 30%. A consensus regarding the standard management of patients with recurrent or refractory disease has yet to be obtained and new drugs are needed.
The Lancet Oncology , commentaire, 2019